BCL2 and cancer: Taken together, the results of this study showed that the reductions of anti-apoptotic proteins and alterations to MCL1 splicing is an important mechanism of CLK-induced cell death and the use of CLK inhibitors in combination with Bcl-xL/Bcl-2 inhibitors presents an option for cancer therapy.